<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT02616744</url>
  </required_header>
  <id_info>
    <org_study_id>BONADIUV</org_study_id>
    <nct_id>NCT02616744</nct_id>
  </id_info>
  <brief_title>Study of Oral Bisphosphonate for Osteopenic Women Treated With Adjuvant Aromatase Inhibitors</brief_title>
  <acronym>BONADIUV</acronym>
  <official_title>A Single--blind, Randomized, Placebo--controlled Phase II Study to Evaluate the Impact of Oral Bisphosphonate Treatment on Bone Mineral Density in Osteopenic Women Receiving Adjuvant Aromatase Inhibitors - BONADIUV Trial</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Azienda Ospedaliero-Universitaria Careggi</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Azienda Ospedaliero-Universitaria Careggi</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      A single--blind, randomized, placebo--controlled phase II study to evaluate the impact of
      oral bisphosphonate treatment on bone mineral density in osteopenic women receiving aromatase
      inhibitors as adjuvant treatment.
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      Aromatase inhibitors (AIs) are the adjuvant treatment of choice in postmenopausal women with
      early, hormone receptor-positive breast cancer (BC), because they produce improved survival
      rates compared with tamoxifen. Progressive bone loss and subsequent fractures are associated
      with adjuvant AIs, administered either alone or sequentially after tamoxifen in
      postmenopausal women with early BC. Recent findings of National Surgical Adjuvant Breast and
      Bowel Project (NSABP) B-34 also suggest that bisphosphonates might have anticancer benefits
      for older postmenopausal women. &quot;BONADIUV&quot; trial is a single-blind, randomized,
      placebo-controlled study designed to evaluate the impact of bisphosphonate treatment on bone
      mineral density (BMD) in women taking AIs.

      Patients undergo a baseline BMD and if they result osteopenic (lumbar spine and/or trochanter
      -1&lt; T-score &lt;2.5), they are randomized in a 1:1 ratio to receive either placebo or oral
      ibandronate. All patients receive oral supplementation of calcium and Vitamin D3, once daily
      for two years. Study duration is 2 year, with planned six-months evaluation.

      A total of 72 patients per arm of treatment are needed to obtain a 85% statistical power in
      order to detect a 2% BMD mean difference between the two arms. Considering a 15% dropout,
      around 82 patients per arm are planned to be enrolled.
    </textblock>
  </detailed_description>
  <overall_status>Completed</overall_status>
  <start_date>January 2011</start_date>
  <completion_date type="Actual">May 2016</completion_date>
  <primary_completion_date type="Actual">May 2016</primary_completion_date>
  <phase>Phase 2</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>Single (Participant)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Lumbar spine and trochanter T-score mean difference as measure of BMD variation</measure>
    <time_frame>2 years</time_frame>
  </primary_outcome>
  <secondary_outcome>
    <measure>Number of Participants with Adverse Events as a Measure of Safety and Tolerability</measure>
    <time_frame>2 years</time_frame>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Actual">171</enrollment>
  <condition>Breast Cancer</condition>
  <arm_group>
    <arm_group_label>Arm A: Ibandronic acid</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Ibandronic acid 150 mg per os per month for two years</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Arm B: Placebo</arm_group_label>
    <arm_group_type>Placebo Comparator</arm_group_type>
    <description>Placebo per os per month for two years</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Ibandronic acid</intervention_name>
    <description>150 mg per month oral ibandronate</description>
    <arm_group_label>Arm A: Ibandronic acid</arm_group_label>
    <other_name>Ibandronate</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Placebo</intervention_name>
    <description>1 oral capsule of placebo per month</description>
    <arm_group_label>Arm B: Placebo</arm_group_label>
    <other_name>Placebo capsule</other_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Diagnosis of hormone-receptor positive early breast cancer

          -  Menopausal status

          -  Age &lt; 75 years

          -  Written informed consent

        Exclusion Criteria:

          -  Premenopausal status at time of randomization

          -  Comorbidities with increased risk of osteoporosis (primary hyperparathyroidism,
             hyperthyroidism, rheumatoid arthritis)

          -  BMI &lt; 18

          -  Chronic use of steroids

          -  Use of bisphosphonates at time of randomization

          -  Psychiatric disorders
      </textblock>
    </criteria>
    <gender>Female</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>75 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Lorenzo Livi, Professor</last_name>
    <role>Principal Investigator</role>
    <affiliation>AOU Careggi - University of Florence, Florence, Italy</affiliation>
  </overall_official>
  <overall_official>
    <last_name>Meattini Icro, M.D.</last_name>
    <role>Principal Investigator</role>
    <affiliation>AOU Careggi - University of Florence, Florence, Italy</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Radiation Oncology Unit, Azienda Ospedaliero-Universitaria Careggi</name>
      <address>
        <city>Florence</city>
        <zip>50134</zip>
        <country>Italy</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>Italy</country>
  </location_countries>
  <verification_date>May 2016</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>November 24, 2015</study_first_submitted>
  <study_first_submitted_qc>November 25, 2015</study_first_submitted_qc>
  <study_first_posted type="Estimate">November 30, 2015</study_first_posted>
  <last_update_submitted>May 29, 2016</last_update_submitted>
  <last_update_submitted_qc>May 29, 2016</last_update_submitted_qc>
  <last_update_posted type="Estimate">June 1, 2016</last_update_posted>
  <responsible_party>
    <responsible_party_type>Principal Investigator</responsible_party_type>
    <investigator_affiliation>Azienda Ospedaliero-Universitaria Careggi</investigator_affiliation>
    <investigator_full_name>Lorenzo Livi</investigator_full_name>
    <investigator_title>Full Professor</investigator_title>
  </responsible_party>
  <keyword>aromatase inhibitors</keyword>
  <keyword>breast cancer</keyword>
  <keyword>bone mineral density</keyword>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Aromatase Inhibitors</mesh_term>
    <mesh_term>Ibandronic acid</mesh_term>
    <mesh_term>Diphosphonates</mesh_term>
  </intervention_browse>
  <patient_data>
    <sharing_ipd>Undecided</sharing_ipd>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

